Previous studies demonstrated that both ICPs (e.g., PD-L1 and TIM-3) and immunogenic cell death (ICD) modulators (e.g., CALR and HMGB1) play critical roles in modulating the host anti-tumor immunity, which could influence the efficacy of mRNA vaccine. Here, CALR is linked to neoplasm.